IGC Pharma (IGC) Liabilities and Shareholders Equity (2011 - 2026)

IGC Pharma (IGC) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $9.2 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $9.2 million, up 5.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.6 million (down 5.68% YoY), and the FY2026 annual result was $9.2 million, up 5.01% from the prior year.
• Liabilities and Shareholders Equity declined to $9.2 million in Q1 2026 per IGC's latest filing, from $9.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $26.8 million in Q1 2022 and troughed at $7.9 million in Q2 2025.
• A 5-year average of $14.1 million and a median of $10.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity plunged 43.9% in 2023, then gained 6.98% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $20.1 million in 2022, then sank by 43.9% to $11.3 million in 2023, then declined by 19.37% to $9.1 million in 2024, then advanced by 6.98% to $9.7 million in 2025, then retreated by 5.43% to $9.2 million in 2026.
• Business Quant data shows IGC's Liabilities and Shareholders Equity at $9.2 million in Q1 2026, $9.7 million in Q4 2025, and $9.7 million in Q3 2025.